Gland Pharma Q2 FY27: revenue up 23.3% to ₹1,834 Cr, net profit up 58.3% to ₹291 Cr
Results · Finvezto · 6 Nov 2026 · Gland Pharma (GLAND)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 1,834 | +1.8% | +23.3% |
| Operating profit | 484 | -1.1% | +54.2% |
| Net profit | 291 | -8.3% | +58.3% |
| Operating margin | 26.4% | -0.8 pp | +5.3 pp |
| Net margin | 15.9% | -1.7 pp | +3.5 pp |
Key points
- For the second quarter ended September 30, 2026 (Q2 FY27), Gland Pharma Limited reported consolidated revenue from operations of Rs 1,833.60 crore (up 23% YoY), EBITDA of Rs 480.40 crore (up 53% YoY), and profit after tax of Rs 290.80 crore (up 58% YoY). NSE filing
- Growth was driven by the CDMO division, which increased 31% year-on-year to Rs 822.70 crore, while US market revenue rose 42% to Rs 1,179.50 crore. NSE filing
- Revenue was ₹1,834 Cr, up 23.3% on a year earlier and up 1.8% on the quarter before. Finvezto data
What to watch
- Operating margin over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26): 25.7%, 29.4%, 27.2%, 26.4%.
- Net profit over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26), ₹ Cr: 262, 367, 317, 291.
Links
NSE filing (PDF) · Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.